Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2017

View Archived Issues

Stealth BioTherapeutics initiates phase I/II trial of SBT-20

ImmunGene regains rights to three antibody-interferon fusion product candidates

Cancer Targeted Technology creates PSMA inhibitor with improved in vivo characteristics

Nymox seeks approval of fexapotide triflutate for BPH in five European countries

Servier and Miragen extend cardiovascular collaboration

Novel anti-TIGIT antibody OMP-313M32 induces antitumor immune response in vivo

FDA accepts for review Xeljanz sNDAs for psoriatic arthritis

Denovo Pharmatech's TLR8 agonist DN-A1 is in late-stage preclinical development

Bristol-Myers Squibb initiates first-in-human study of BMS-986218 in advanced solid tumors

YL-13027 is a novel TGFR-1 inhibitor with promising immunotherapeutic properties in vivo

New phase I trial investigates MK-5160 in type 1 and type 2 diabetes

Xultophy launched in U.S.

Celgene reviews highlights of first quarter 2017

Taiho studies TAS-4466 for multiple myeloma and lymphoma in new phase I/II trial

Novel selective and potent CDK8 inhibitors show promising anticancer efficacy in vivo

Novartis initiates phase I trial of NIS-793 with PDR-001 for advanced malignancies

TaiMed submits ibalizumab BLA to FDA for treatment of multidrug-resistant HIV-1

AbbVie reviews key events from first quarter 2017

Poxel reports promising topline data from Japanese phase IIb study of imeglimin for type 2 diabetes

Bristol-Myers Squibb presents apelin receptor agonists

OncoTherapy Science compound sensitizes breast cancer cells to doxorubicin via SUV39H2 inhibition

BioPharmX's phase IIb study of BPX-011 in acne meets primary endpoint

F. Hoffmann-La Roche AG discovers HBV capsid inhibitors

Melinta to present subgroup analysis from Baxdela phase III program

Can-Fite Biopharma set to begin phase II trial of namodenoson in NAFLD

Novartis exercises license option for emricasan

First patient dosed in first-in-human phase I/II trial of RGT-100

Rydapt available for order in U.S.

Heat Biologics completes acquisition of Pelican Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...